Trials / Unknown
UnknownNCT03389659
XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC
A Randomized, Multicenter, Double-blinded, Phase III Study of Vitamin D3 in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine as First-line Chemotherapy in Previously Untreated Advanced or Metastatic Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 750 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a randomized,multicenter, double-blinded,phase III study. To explore the affection of vitamin D3 in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine as first-line chemotherapy in previously untreated advanced or metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vitamin D3 | vitamin D3 400IU\*5pills po. qd continue to disease progression |
| DRUG | Placebo | placebo 5 pills po. qd continue to disease progression |
Timeline
- Start date
- 2018-02-01
- Primary completion
- 2021-12-01
- Completion
- 2022-06-01
- First posted
- 2018-01-03
- Last updated
- 2018-01-03
Source: ClinicalTrials.gov record NCT03389659. Inclusion in this directory is not an endorsement.